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Gadolinium-Based MRI Contrast Agents Induce Mitochondrial
Toxicity and Cell Death in Human Neurons, and Toxicity Increases
With Reduced Kinetic Stability of the Agent
Danielle V. Bower, MD, PhD,*† Johannes K. Richter, MD,* Hendrik von Tengg-Kobligk, MD,*†
Johannes T. Heverhagen, MD, PhD,*† and Val M. Runge, MD*†Objectives: This preclinical study was devised to investigate potential cellular
toxicity in human neurons induced by gadolinium-based contrast agents (GBCAs) used
for contrast-enhanced magnetic resonance imaging (MRI). Neurons modeling a subset
of those in the basal gangliawere tested, because the basal ganglia region is 1 of 2 brain
regions that displays the greatest T1-dependent signal hyperintensity changes.
Methods: Eight GBCAs were tested. Dopaminergic neurons modeling a subset
of those in the basal ganglia were differentiated from an established human neu-
roblastoma cell line and exposed to increasing concentrations of each agent for
7 days. The tested dosages ranged from clinically relevant concentrations mea-
sured in some autopsy patients who had received repeated injections of contrast
for MRI, to higher concentrations to reveal dose-dependent toxicity trends. Cell
death, mitochondrial membrane potential, mitochondrial oxidative capacity, and
mitochondrial function measured by oxygen consumption were quantified in
cells treated with each GBCA or the osmolality control mannitol and compared
to untreated cells which served as a negative control.
Results:Mannitol caused no change from negative controls in any of the tests, at
any concentration tested. For all GBCAs, cell death increased with exposure
dose, with toxicity at clinically relevant doses for agents with lower kinetic stabil-
ity. Reduction of mitochondrial membrane potential and oxidative respiratory
function also generally mirrored the agents' structural kinetic stabilities, with
greater impairment at lower concentration for the less stable agents.
Conclusions: In human neurons modeling a subset of those in the basal ganglia,
these results demonstrate a toxic effect of gadolinium-containing MRI contrast
agents on mitochondrial respiratory function and cell viability. Toxicity increases
as agent concentration increases and as the kinetic stability of the agent decreases.
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Copyright © 2019 Wolters Kluwer HG adolinium-based contrast agents (GBCAs) for contrast-enhancedmagnetic resonance imaging (MRI) have been used for decades
and are generally well-tolerated and considered safe for use in patients
who have normal kidney function.1 However, the known deposition of
gadolinium in tissues throughout the body, and particularly, accumula-
tion in regions of the brain, has renewed concerns about the long-term
safety of these agents. Kanda et al2 first highlighted the changes in
T1-dependent MRI signal intensity after MRIs without contrast agent
in the brains of patients with normal renal function who had received
multiple prior injections of gadolinium-containing contrast. The basal
ganglia and cerebellar dentate nucleus are the brain regions that most
strongly exhibit these effects.
Multiple subsequent studies have shown that such T1-dependent
signal intensity changes persist in patients who have received repeated
injections of the linear GBCAs, but repeated use of the macrocyclics re-
sults in minimal to no persistent change.3–12 To explain these findings,
studies have evaluated the entry into and clearance of contrast agents
from the brain.13–16 Experiments in rats provide evidence that the linear
agents dissociate gadolinium from their chelate, which precipitates or
binds to macromolecules and persists long-term within brain tissue.17
In contrast, the macrocyclic agents predominantly remain as soluble, in-
tact complexes and are gradually removed from the brain within ap-
proximately 5 months.17–19 Increasing evidence argues that all agents
reside within the interstitium of human brain tissue for some period of
time, where they may be taken up into various cell types, including
glia20 and neurons.21
During this time, emerging reports of possible clinical symptoms
including headache, confusion, and bone and limb pain experienced by
patients after a contrast-enhanced MRI scan have been published.22–25
Recognition of these symptoms, the persistent T1-dependent signal in-
tensity changes in the brain, and the detection of gadolinium in brain tis-
sue of autopsy patients21,26,27 necessitate clarification as to whether
these agents cause toxicity in the brain. Yet, to date, it remains unknown
whether these agents induce toxic effects on the cellular function of
human neurons.
In the current study, we sought to identify whether GBCAs are
toxic to the cellular function of differentiated human neurons that are
representative of those found in one of the brain regions with high
T1-dependent MRI signal intensity changes. As such, we incubated a
subset of basal ganglia neurons with concentrations of each contrast
agent ranging from clinically relevant doses (based on reported amounts
of gadolinium measured in some autopsy patients) to higher doses, and
investigated dose-dependent effects on cell viability and function.MATERIALS AND METHODS
MRI Contrast Agents
The commercial MRI contrast agents were obtained from the
manufacturers as noted in Table 1. We were unable to obtain gadover-
setamide, and we were only able to obtain gadopentetate dimegluminewww.investigativeradiology.com 453
ealth, Inc. All rights reserved.
TABLE 1. Contrast Agents
Generic Name
(Trade Name) Manufacturer Structure Ionicity
Osmolality at 37°C
(mOsm/kg H2O)† Excess Chelate Log Kcond‡
Dissociation Half-Life
T1/2 (Kinetic Stability),
pH 1.0, 25°C
NF-gadodiamide Linear Nonionic 739 0 14.9 <5 s
Gadodiamide (Omniscan) GE Healthcare Linear Nonionic 789 25 mmol/L caldiamide
Na + salt
Ca-DTPA-BMA
14.9 <5 s
Gadopentetate dimeglumine
(Magnevision, Magnevist)*
Bayer
Healthcare
Linear Ionic 1960 1 mmol/L free DTPA 17.7 <5 s
Gadoxetate disodium
(Primovist/Eovist)
Bayer
Healthcare
Linear Ionic 688 1.5 mmol/L trisodium
salt Ca-EOB-DTPA
18.7 <5 s
Gadobenate dimeglumine
(MultiHance)
Bracco
Imaging
Linear Ionic 1970 0 18.4 <5 s
Gadoterate meglumine
(Dotarem)
Guerbet Macrocyclic Ionic 1350 0 19.3 338 h
Gadobutrol
(Gadovist/Gadavist)
Bayer
Healthcare
Macrocyclic Nonionic 1603 1.0 mmol/L Na + salt
Ca-BT-DO3A
14.7 43 h
Gadoteridol (ProHance) Bracco
Imaging
Macrocyclic Nonionic 630 0.5 mmol/L Ca2 + salt
[Ca-HP-DO3A]2
17.1 3.9 h
*We were unable to obtain Magnevist, so we used Magnevision, which is a generic preparation with the same chemical formula as Magnevist.
†Osmolality of the pharmaceutical preparation, except for nonformulated gadodiamide, which is a nonpharmaceutical research preparation.
‡Conditional thermodynamic stability constant at pH 7.4 reflecting the affinity of gadolinium for its ligand.
The values in the table were obtained from Idée et al,28 Port et al,29 and Runge et al.30
Bower et al Investigative Radiology • Volume 54, Number 8, August 2019as Magnevision rather than Magnevist, but these two have the same
chemical formula. The noncomplexed gadodiamidewas kindly provided
by the research and development division of Guerbet. The values in the
table were obtained from Idée et al,28 Port et al,29 and Runge et al.30
Cell Culture and Differentiation of
Dopaminergic Neurons
SH-SY5Y human neuroblastoma cells were obtained fromATCC
(CRL-2266, Lot #63290668). Adherent and suspension cells were
propagated at 37°C and 5% CO2 in sterile filtered (ThermoFisher
450–0045) SH-SY5Ymedia (see Table 2 for all medias used), and pas-
saged 1:10 or higher usingAccutase (ThermoFisher A1110501) around
80% confluency. Cells were frozen in liquid nitrogen in SH-SY5YTABLE 2. Cell Culture Medias
SH-SY5Y Media Differentiation Media 1
DMEM/F12 (Bioswisstec AG FG4815) DMEM/F12
15% FBS (ThermoFisher 10270,
heat inactivated)
1% FBS
1% nonessential amino acids
(NEAA) (ThermoFisher 11140035)
1% NEAA
1% penicillin/streptomycin (P/S)
(ThermoFisher 15140122)
1% P/S
10 μM retinoic
acid (Sigma R2625)
Differentiation Media 2 Phosphate-Free IncubationMedia
Neurobasal media (ThermoFisher
12348017)
DMEM without phosphate
(ThermoFisher 11971025)
1X B27 (ThermoFisher 17504044) 1X B27
1% Glutamax (ThermoFisher 35050061) 1% Glutamax
20 mM KCl 20 mM KCl
1% P/S 1% P/S
80 nM phorbol 12-myristate 13-acetate
(PMA) (Sigma P8139)
80 nM PMA
454 www.investigativeradiology.com
Copyright © 2019 Wolters Kluwer Hmedia with 5% vol/vol DMSO. To differentiate, 2–4  104 SH-SY5Y
cells were plated per well in 200 μL media in 96-well imaging dishes
(Eppendorf 0030 741.013). The following day, the media was changed
to differentiation media 1 for 4 days, followed by a further 7 days in dif-
ferentiation media 2.
Incubation of Neurons With MRI Contrast Agents and
Assessment of Cellular Toxicity
Following the 11-day differentiation protocol, neurons were cul-
tured in phosphate-free media to avoid gadolinium phosphate precipita-
tion upon addition of MRI contrast agents. Indeed, we did not observe
visible precipitates in our cultures. Briefly, each contrast agent was di-
luted in water for injection to a stock concentration of 0.25 M. Each
agent was then diluted sequentially to final concentrations of 10 mM,
1 mM, 100 μM, and 50 μM in phosphate-free media. Individual wells
of neurons were incubated with each concentration of contrast agent
in triplicate or more for 7 days.
After incubationwith contrast agent, cellular toxicity was assessed
by preincubating cells for 45 minutes with fluorescent indicators and im-
aging with a Zeiss LSM 710 confocal microscope and Plan-Apochromat
20/0.8 M27 objective. For quantification of cell death, all cell nuclei
were labeled with 5 μg/mL Hoechst 33342 (Thermo Scientific 62249),
which is a classic compound used to stain DNA.31 The Hoechst 33342
was excited at 405 nm with emissions collected at 422 to 498 nm with
a 4 μM pinhole. All dead cells were labeled with 2 μg/mL propidium
iodide (Sigma P4170), excited at 405 nm and imaged at 600 to
755 nm. Apoptotic cells with active caspase 3 or 7 were labeled with
2 μM CellEvent caspase 3/7 reagent (ThermoFisher C10723), excited
at 488 nm and imaged at 492 to 568 nm. Mitochondrial membrane po-
tential was assayed with freshly prepared 10 μM TMRE (Sigma
87917), excited at 561 nm and imaged at 570 to 754 nm with a 2 μm
pinhole and 2 μm interval stack centered at the brightest plane. Mito-
chondrial oxidative capacity was assayed with freshly prepared 5 μM
DCFH2-DA (Sigma D6883), excited at 488 nm and imaged at 493
to 575 nm with a 2 μm pinhole and 2 μm interval stack centered at
the brightest plane. Scan speed was 8, with averaging of 2 and zoom© 2019 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
Investigative Radiology • Volume 54, Number 8, August 2019 Mitochondrial Toxicity and Cell Death in Neurons1. When signal intensity was to be quantified, laser power and PMT
gain were identical across all samples within an experiment, and nor-
malization to negative controls lacking contrast agent was performed
within each experiment.
Mannitol (Sigma M4125) was selected as an osmolality control.
However, due to a miscalculation, the highest concentration of mannitol
tested did not equal the osmolality of the high osmolality contrast agents
when applied at the concentration of 10 mM. At 10 mM, the osmolality
of the following agents are: gadopentetate dimeglumine, 39.2 mOsm/kg;
gadobenate dimeglumine, 39.4 mOsm/kg; gadoterate meglumine,
27 mOsm/kg; and gadoxetate disodium, 27.5 mOsm/kg. The highest
concentration of mannitol tested had an osmolality of 24 mOsm/kg.
All other contrast agents have an osmolality less than 24 mOsm/kg
at a concentration of 10 mM, and their osmolalities were therefore
properly controlled. At a concentration of 1 mM, the osmolality of
all contrast agents is below 24 mOsm/kg, and thus osmolality at this
concentration was properly controlled.
Cumulative signal intensity summing all pixels in a region of
interest was quantified for mitochondrialmembrane potential and oxidative
capacity using ImageJ with a 4.98 4.98-μmoval region of interest on the
brightest image slice and averaging 15 or more cells per sample. To quan-
tify cell death, all cells labeled by propidium iodide or activated caspase
were individually counted and compared with the total number of nuclei
(by Hoechst 33342 label) in the image. Repeat quantification reproduc-
ibility was within 1%. Interreader reproducibility was within 2%.
Characterization of mRNA Expression
mRNAwas collected from SH-SY5Y neuroblasts and from neu-
rons after differentiation plus an additional 7 days' culture in phosphate-
free media using the Dynabeads mRNA Direct Kit (Ambion 61011).
quantitative real-time polymerase chain reaction (qRT-PCR) was per-
formed using the Luna Universal One-Step RT-qPCR Kit (New England
BioLabs E3005) on an Applied Biosystems 7500 Real-Time Fast PCR
machine. See Table 3 for the primers used. Results were analyzed using
the ΔΔCT method.
Seahorse XFe Assessment of Mitochondrial Respiration
Approximately 1  104 SH-SY5Y cells were plated per well in
Seahorse 96-well culture plates and differentiated as aforementioned.
Cells were incubated as aforementioned with MRI contrast agents di-
luted in phosphate-free media for 7 days. The oxygen consumption
rate and extracellular acidification rate were measured using a
Seahorse XFe96 Analyzer with the Cell Mito Stress Test Kit (Bucher
103015–100) and FluxPack (Bucher 102601–100) using BaseMedium
(Bucher 102353–100) supplemented with D-glucose (Merck 1.08337.5000),
sodium pyruvate (Sigma P5280), and L-glutamine (ThermoFisher
25030081), and adjusted to pH 7.4 and sterile filtered according to
the manufacturer's instructions. One micromolar of oligomycin A,
1.5 μM of FCCP, and 0.5 μM of rotenone/antimycin A were injectedTABLE 3. qRT-PCR Primers
Target Forward
Neurogenin 1 5′-AGCGCCTTTCTATCTGT
Tau 5′-ATGCACCAAGACCAAGA
Dopamine receptor 2 5′-GGCTCCACTAAAGGAGG
Dopamine receptor 3 5′-ACCCCACGAATGTTTCA
Dopamine transporter 5′-TCACCACCTCCATCAAC
Neural enolase 2 5′-TGTGCATAGTGCTGGGA
Nestin 5′-GTAGCTCCCAGAGAGGG
Beta-actin 5′-CGAGGACTTTGATTGCACA
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2019 Wolters Kluwer Hto assay the basal respiration rate, ATP production, maximal respira-
tion, and nonmitochondrial oxygen consumption. Data were analyzed
with Agilent Wave 2.4 software and macros, with cell numbers normal-
ized by visual counting and CASY cell counts (OMNI Life Science) af-
ter each experiment.
Statistics
Two-tailed t-tests for independent means were used to compare
each test sample to the negative control for statistical significance. Cal-
culations were performed using the t-value calculator: https://www.
socscistatistics.com/tests/studentttest/Default2.aspx.
RESULTS
Differentiated Human Neurons Display Neural
Morphology and Express Dopaminergic Markers
Neurons were differentiated from a human neuroblastoma cell
line into dopaminergic neurons as a representative model of some neu-
rons in the basal ganglia, which is one of the 2 brain regions exhibiting
highest T1 signal augmentation after repeat administration of GBCAs.32
Differentiation proceeded with retinoic acid followed by a phorbol ester
and neural-specific growth factors according to the protocol in Figure 1,
A and B. After 7 days of further culture in phosphate-free media without
contrast agents, cells displayed an interconnected network of elongated
axons (Fig. 1C), in contrast to the round cell morphology and short
dendritic projections of the neuroblasts (Fig. 1A). mRNA expression
analysis verified significantly increased expression of markers of
mature dopaminergic neurons, including dopamine receptors, dopamine
transporter, and mature neuron-specific enzymes, transcription factors,
and structural proteins (Fig. 1D).
We next used differentiated human neurons to investigate cellular
toxicity due to exposure to GBCAs. Each GBCAwas applied at 50 μM,
100 μM, 1mM, and 10mM concentrations. A range of concentrations of
gadolinium have been reported to have been measured in human brain
tissue of autopsy patients who received various different GBCAs and
numbers of doses,21,26,27 with higher concentrations reported by
McDonald et al. With a molecular weight of 157.25 g/mol for gado-
linium, 20 μg Gd/g brain tissue measured in some autopsy patients
with repeat GBCA exposure21 corresponds to 127 μM concentration
of gadolinium in brain tissue, although this value is an approximation
as the amount of water lost during tissue desiccation is uncertain.
Fifty micromolar and 100 μM were selected as “clinically relevant”
concentrations after receipt of repeated doses of GBCA, and 1 mM
and 10 mM were tested to reveal toxicity trends with higher dose.
Cell Death Increases With Increasing GBCA Dose and
Lower Kinetic Stability of the Agent
For neurons exposed to GBCAs, the percentage of dead cells la-
beled by propidium iodide due to membrane compromise and apoptoticReverse
CCG-3′ 5′-AGGAAGCCGGATAGGTCACT-3′
GGG-3′ 5′-CCGCTGTTGGAGTGCTCTTA-3′
CTG-3′ 5′-GTTTTGCCATTGGGCATGGT-3′
GGA-3′ 5′-ATGCCAAGGGGCTTCACATT-3′
TGC-3′ 5′-TGATGAAGAAGACCACCGCC-3′
TGG-3′ 5′-GACACATCGTTCCCCCAAGT-3′
GAA-3′ 5′-CTCTAGAGGGCCAGGGACTT-3′
TTGTT-3′ 5′-TGGGGTGGCTTTTAGGATGG-3′
www.investigativeradiology.com 455
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FIGURE 1. Differentiation of human neurons that highly express dopaminergic markers and display neural morphology. A, Undifferentiated human
SH-SY5Y neuroblastoma cells are maintained in culture. Image depicts these nondifferentiated cells. B, Differentiation proceeds in 3 steps utilizing
retinoic acid and a phorbol ester alongside depletion of serum and phosphate and provision of neural growth factors as shown. Differentiated neurons
display elaborate axon networks (C) and highly express markers of dopaminergic neurons (D), fold change in expression and 95% confidence interval
compared with undifferentiated cells. Fold change in expression greater than 50 was plotted as 50.
Bower et al Investigative Radiology • Volume 54, Number 8, August 2019cells labeled with caspase reagent were quantified relative to total cell
number and normalized to negative controls that had not been exposed
to contrast agents (Fig. 2). In general, caspase reagent labeled slightly higher
proportions of cells than propidium iodide. This was likely due to apoptotic
cells activating caspase before membrane integrity became compromised.
After 7 days of exposure, cells treated with nonformulated (NF)
gadodiamide and gadodiamide showed the highest rates of cell death at
1.77- and 1.52-fold, respectively, relative to negative controls at 50 μM
(Fig. 2A). At 10 mM of gadodiamide, dead cell numbers were double
that of negative controls. Gadopentetate dimeglumine also caused
statistically higher rates of cell death (approximately 1.25-fold) compared
with controls at 50 μM and 100 μM.456 www.investigativeradiology.com
Copyright © 2019 Wolters Kluwer HWith gadoxetate disodium and gadobenate dimeglumine, cell
death was only statistically elevated at 1 mM and 10 mM (to approxi-
mately 1.5- to 1.65-fold relative to controls).
The macrocyclic agents gadoterate meglumine, gadobutrol, and
gadoteridol demonstrated no statistical increase in cell death at 50 μM
or 100 μM (Fig. 2A). Cell death increased with dose to approximately
1.55-fold (gadoterate meglumine), 1.30-fold (gadobutrol), and 1.4-fold
(gadoteridol) at 10 mM. The osmolality control mannitol caused no
increased cell death compared with negative controls. Figure 2, B to D
show selected representative images of the labeled cell nuclei and dead
cell markers for gadopentetate dimeglumine (Fig. 2B), gadoteridol
(Fig. 2C), and negative control (Fig. 2D).© 2019 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
FIGURE 2. Cell viability drops with lower kinetic stability contrast agents and higher dose. Neurons incubated without (negative control) or with the
specified agent and dose for 7 days were assayed for propidium iodide (P) uptake or positive caspase indicator (C) to quantify dead and apoptotic cells,
respectively. A, The plot depicts the mean and SEM (error bars) of the proportion of dead and apoptotic cells normalized to negative controls at each
tested concentration for the osmolality control mannitol and each contrast agent. *P < 0.05; **P < 0.01. B to D, The images show representative
examples of cells labeled for Hoechst 33342 (all cell nuclei), propidium iodide, or caspase at each concentration for samples treated with (B)
gadopentetate dimeglumine, (C) gadoteridol, and (D) no agent (negative control). Scale bar = 50 μm for all images.
Investigative Radiology • Volume 54, Number 8, August 2019 Mitochondrial Toxicity and Cell Death in Neurons
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Bower et al Investigative Radiology • Volume 54, Number 8, August 2019Mitochondrial Membrane Potential Decreases With
Increasing GBCA Dose and Lower Kinetic Stability
of the Agent
Next, we investigated a potential effect of GBCAs on mito-
chondrial function. A reduction in mitochondrial membrane poten-
tial impairs ATP production and can lead to apoptosis.33
After 7 days of incubation with GBCAs, mitochondrial mem-
brane potential decreased with increasing concentration of contrast
agent (Fig. 3). The potential also decreased more as the kinetic stability
of the agents decreased. The most severe reduction in membrane po-
tential was caused by NF-gadodiamide (0.71 relative to a control
value of 1 at 50 μM and 0.36 at 10 mM; Fig. 3A). Gadodiamide
and gadopentetate dimeglumine caused comparable impairment (ap-
proximately 0.71 relative to controls at 50 μM and 0.58 at 10 mM).
Gadoxetate disodium caused less, but still statistically significant,
impairments across the dose range. Gadobenate dimeglumine showed
minimal effect at low dose but severe impairment at higher dosesFIGURE 3. Mitochondrial membrane potential weakens with lower kinetic s
potential was quantified in neurons incubated without (negative control) or
mean and SEM (error bars) of the membrane potential of neurons treated w
B and C, The images depict the fluorescent mitochondrial membrane pote
gadobenate dimeglumine or (C) gadoterate meglumine in comparison to n
for all images.
458 www.investigativeradiology.com
Copyright © 2019 Wolters Kluwer H(0.70 and 0.50 relative to controls at 1 mM and 10 mM, respectively;
Fig. 3, A and B).
The macrocyclic agents generally exhibited less impact. Af-
ter 7 days, membrane potential ranged from 0.96 (gadobutrol) to
no impact (gadoterate meglumine and gadoteridol) at the lowest
2 concentrations (Fig. 3A).
At 10 mM, potential dropped to 0.75 (gadoterate meglumine;
Fig. 3, A and C) and around 0.94 for gadobutrol and gadoteridol. The os-
molality control mannitol caused no impact onmembrane potential at any
dose. Figure 3, B and C depict selected representative images of the cells.
Mitochondrial Oxidative Respiratory Capacity
Decreases With Increasing GBCA Dose and Lower
Kinetic Stability of the Agent
Because mitochondrial membrane potential was affected by
GBCAs, we tested for a corresponding impairment in mitochondrial
oxidative respiratory function (Fig. 4). The fluorescent indicatortability contrast agents and higher dose. The mitochondrial membrane
with the specified agent and dose for 7 days. A, The graph depicts the
ith each agent, normalized to negative controls. *P < 0.05; **P < 0.01.
ntial indicator in representative examples of neurons treated with (B)
eurons treated without agent (negative controls). Scale bar = 25 μm
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 4. Mitochondrial oxidative respiratory capacity diminishes with lower kinetic stability contrast agents and higher dose. The mitochondrial
oxidative respiratory capacity was quantified in neurons treated without (negative control) or with the specified agent and dose for 7 days. A, The plot
depicts the mean and SEM (error bars) of the oxidative capacity of neurons treated with each agent, normalized to negative controls. *P < 0.05;
**P < 0.01. B and C, The images depict the fluorescent indicator in representative examples of neurons treated with (B) gadodiamide or (C) gadobutrol
in comparison to neurons treated without agent (negative controls). Scale bar = 25 μm for all images.
Investigative Radiology • Volume 54, Number 8, August 2019 Mitochondrial Toxicity and Cell Death in NeuronsDCFH2-DA enters the mitochondrial matrix where it is oxidized to a
fluorescent state by mitochondrial reactive oxygen species from ox-
idative phosphorylation and thereby serves as an effective indicator of
mitochondrial oxidative respiratory function.34
For all of the contrast agents, mitochondrial oxidative func-
tion decreased with higher agent concentration. After 7 days of in-
cubation with GBCAs, gadodiamide and NF-gadodiamide again
exhibited the greatest impairment, with mitochondrial oxidative ca-
pacity dropping to 0.47 (gadodiamide) or 0.36 (NF-gadodiamide)
compared with the capacity of negative controls with 50 μM
agent concentration (Fig. 4, A and B). At 10 mM concentration of
gadodiamide and NF-gadodiamide, the mitochondrial oxidative
capacity was reduced to 0.19 compared with the capacity of negative
controls. The other linear agents had no statistical impact at 50 μM,
but oxidative function dropped to 0.43 (gadopentetate dimeglumine),
0.24 (gadoxetate disodium), and 0.32 (gadobenate dimeglumine) the
capacity of negative controls with 10 mM agent concentration.
The macrocyclic agents showed no impairment at 50 μM and
much less impairment than the linear agents up to 1 mM concentration
(Fig. 4, A–C). At 10 mM, oxidative capacity was 0.17 (gadoterate© 2019 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2019 Wolters Kluwer Hmeglumine), 0.47 (gadobutrol), and 0.90 (gadoteridol) compared
with that of controls. The osmolality control mannitol demonstrated
no effect on mitochondrial oxidative function for any concentration
tested. Figure 4, B and C show selected representative images of the cells.
Mitochondrial Function Measured by Oxygen
Consumption Decreases With Increasing GBCA Dose
and Lower Kinetic Stability of the Agent
The mitochondrial stress test implemented with the Seahorse
XFe96 Analyzer further assesses mitochondrial function by measuring
the oxygen consumption rate and extracellular acidification rate of
living cells, from which various respiratory parameters and ATP pro-
duction can be measured (Fig. 5). After 7 days of incubation with
50 μM or 100 μM GBCA, no statistically significant differences in
basal respiration rate, ATP production, maximal respiration, or spare
respiratory capacity (maximal-basal respiration) were measured
(Fig. 5, A and B). At 1 mM GBCA concentration, statistically significant
impairments in maximal respiration and spare capacity were observed
for NF-gadodiamide (Fig. 5C).www.investigativeradiology.com 459
ealth, Inc. All rights reserved.
FIGURE 5. Mitochondrial function measured by oxygen consumption declines with lower kinetic stability contrast agents and higher dose.
Oxygen consumption and extracellular acidification rates were measured with a Seahorse XFe96 Analyzer. Basal and maximal respiratory rates, ATP
production, and spare respiratory capacity were quantified. Line graphs plot the oxygen consumption rate (pmol/min/cell count). Bar plots depict
the mean and SEM (error bars) of the derived respiratory parameters for neurons incubated for 7 days without (negative control) or with each
specified agent at concentrations of (A) 50 μM, (B) 100 μM, (C) 1 mM, and (D) 10 mM. *P ≤ 0.05; **P < 0.01.
Bower et al Investigative Radiology • Volume 54, Number 8, August 2019With 10 mM GBCA concentration, the linear agents demon-
strated substantially reduced basal and maximal respiration, spare
capacity, and ATP production (Fig. 5D). The spare capacity for
gadopentetate dimeglumine and ATP production for gadodiamide,
gadopentetate dimeglumine, and gadobenate dimeglumine fell
short of statistical significance (P = 0.08, P = 0.12, P = 0.23,
P = 0.10, respectively), although the standard errors do not overlap
with that of the negative control.460 www.investigativeradiology.com
Copyright © 2019 Wolters Kluwer HWith 10 mM GBCA concentration, the macrocyclic agents
demonstrated some, but less, impairment in all measures, and none
achieved statistically significant deviation from controls (Fig. 5D).DISCUSSION
The growing evidence that GBCAs remain in brain tissue on
the order of months or longer after administration, and that the less© 2019 Wolters Kluwer Health, Inc. All rights reserved.
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gadolinium species that may persist for an indefinite period, necessi-
tates understanding the potential impacts of these agents on cellular
function. In the current study, we demonstrate that GBCAs induce
cell death and have toxic effects on the mitochondrial function of dif-
ferentiated human neurons.
Fifty micromolar and 100 μM concentrations of the contrast
agents were tested as clinically relevant doses because these concentra-
tions correspond to reported amounts of gadolinium measured in brain
tissue of some patients at autopsy after repeated contrast-enhancedMRI
scans.21 Higher concentrations of 1 mM and 10 mMwere also tested to
reveal dose-response toxicity trends.
The highest rates of cell death were caused by formulated and
NF-gadodiamide, followed successively by gadopentetate dimeglumine,
gadoxetate disodium, and gadobenate dimeglumine. The macrocyclics
induced less cell death than the linear contrast agents. Except for the
NF-gadodiamide, which showed high rates of cell death across all con-
centrations, for all other agents, cell death broadly increased with agent
concentration. At concentrations of 50 μM and 100 μM, formulated
and NF-gadodiamide, and gadopentetate dimeglumine statistically sig-
nificantly increased cell death compared with negative controls.
Mitochondrial membrane potential and mitochondrial oxidative
capacity decreased with increasing concentration for all agents. Non-
formulated gadodiamide caused the greatest impairments, followed by
the other linear agents. All linear agents caused statistically significant
reduction of mitochondrial membrane potential and oxidative capacity
at 50 μM and 100 μM concentrations, except that the potential reduc-
tion for gadobenate dimeglumine did not reach statistical significance
until higher concentrations were applied. Macrocyclic agents caused
less effect, particularly at 50 μM and 100 μM concentrations, and sta-
tistically significant impairments at these concentrations (membrane
potential with gadobutrol and oxidation with gadoteridol) were lower
in magnitude. Likewise, NF-gadodiamide was first to elicit impair-
ments in mitochondrial function measured by oxygen consumption,
and at the highest concentration tested, all linear agents but no macro-
cyclics induced statistically significant functional impairments. The os-
molality control mannitol demonstrated no increased cell death or
impact on mitochondrial function in any of the assays used, at any of
the concentrations tested.
Across 5 independent measures of toxicity that we tested, our re-
sults consistently demonstrate that cellular toxicity increases with dose
for all contrast agents, and toxicity broadly increases with decreasing ki-
netic stability of the contrast agent. These findings are consistent with
the association between lower kinetic stability agents having greater in-
cidence of toxicity in other tissues, for instance nephrogenic systemic
fibrosis arising in patients with compromised renal function.35,36 The
mitochondrial toxicity may lead directly to caspase-induced cell death
via well-described pathways, such as involving cytochrome C.37 In-
deed, in rat liver mitochondria, gadolinium causes mitochondrial
swelling by opening the mitochondrial permeability transition pore,
dissipates the inner membrane potential, alters mitochondrial mem-
brane fluidity, and induces apoptosis via cytochrome C release.38
Our results are also consistent with a study performed in rat neurons,
which found that, within 24 hours, gadolinium chloride induces mi-
tochondrial dysfunction and cell death.39 Other cell types exhibit
similar mitochondrial toxicity in response to gadolinium. Treatment
of various multiple myeloma cell lines with motexafin gadolinium
in the presence of ascorbate increases reactive oxygen species production,
decreases mitochondrial membrane potential, and induces apoptosis via
induction of annexin V.40 Likewise, exposing murine macrophages to
GBCAs at concentrations as low as 2.5 μM induces mitochondrial stress
with reactive oxygen species production and reduced mitochondrial
membrane potential and alters inflammatory cytokine production.41 This
study also found greater impairments after treatment with linear agents in
comparison to the macrocyclic gadobutrol.© 2019 Wolters Kluwer Health, Inc. All rights reserved.
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GBCAs. This is a long enough time-frame for cells to recover from im-
mediate, transient toxic effects of the agents, and this indicates that cel-
lular toxicity persists beyond the immediate time of administration. To
exert an effect on mitochondrial function, the agents must be internal-
ized within the cells, which is consistent with prior studies.42 We did
not assay how much agent entered the cells in our system or the form
of the gadolinium, that is, complex, dissociated ion, or bound to a mac-
romolecule. It is possible that the extent of cellular uptake of an individ-
ual agent is the determining factor of the level of resulting toxicity. If
dissociation and indeed binding to a macromolecule promote cellular
uptake, then greater uptake of less kinetically stable agents could ex-
plain the observed results even if all agents, even in complexed form,
are toxic once within a cell.
Robert et al17 demonstrated stable persistence up to 1 year of
gadolinium bound to macromolecules in brains of rats treated with
gadodiamide, in comparison to gadoterate being undetectable after
5 months, with no binding to macromolecules. Thus, in the brain, the
duration of exposure of individual neurons to contrast agent is much
longer than the 7 days of exposure that we tested. Integrated over ex-
tended periods, particularly with dissociation and persistence of the
agents with lower kinetic stability, the effective concentration to which
individual neurons are exposed could be considerably higher than for
just 7 days of exposure at a given dose. Therefore, our results emphasize
the importance of the complete clearance of intact complex from the
brain (and other tissues), as persistence prolongs the opportunity for
gadolinium to dissociate, particularly from the lower kinetic stability
agents, and for gadolinium species to be taken up into cells. Similarly,
the cumulative administered dose of gadolinium within a certain time
frame is also important, as the total concentration will accrue if
contrast-enhanced MRI scans are repeated before the contrast agent
has completely cleared from the previous scan. Once they enter cells,
our results indicate that these agents do cause toxicity and induce apo-
ptosis in human neurons.
This study was conducted in cell culture, which has its inherent
limitations in directly applying results to human beings. First, contrast
agents in culture medium have easy access to cell membranes. Second,
the medium itself is clearly different from the interstitium in human
brain. Third, cells in culture inherently have a different environment
to those in the brain and do not replicate the tissue and synaptic com-
plexity in vivo. Nevertheless, controlled, systematic testing to identify
and characterize a potential toxic effect of GBCAs necessitated an ac-
cessible, reproducible system, which cells in culture provide. We there-
fore were able to test all the trademark GBCAs that we could obtain.
In addition, a miscalculation in preparing our osmolality controls
resulted in the osmolality of our highest concentration of mannitol not
equaling the osmolalities of the highest osmolality contrast agents at
the 10 mM concentration: the highest osmolality of mannitol tested
was 24 mOsm/kg, compared with 27 mOsm/kg for gadoterate
meglumine, 27.5 mOsm/kg for gadoxetate disodium, 39.2 mOsm/kg
for gadopentetate dimeglumine, and 39.4 mOsm/kg for gadobenate
dimeglumine. Thus, through the 1 mM concentration, the osmolalities
of all contrast agents were properly controlled, but for the highest con-
centration tested (10 mM), the osmolalities of these 4 contrast agents
was not fully controlled. Nevertheless, the measured toxicity did not
parallel the osmolality of the agents. If osmolality had been responsible
for the observed toxicity, we would have expected gadopentetate
dimeglumine and gadobenate dimeglumine to be the most toxic, and
this was not the case.
Finally, the ideal system for these experiments would have been
to use primary human cerebellar neurons from the dentate nucleus;
however, the difficulty of obtaining and culturing such neurons would
greatly reduce the feasibility of conducting such a study. Utilizing dif-
ferentiated human neurons from an established cell line ensured the fea-
sibility and timeliness of the study. Within the basal ganglia, the globuswww.investigativeradiology.com 461
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Bower et al Investigative Radiology • Volume 54, Number 8, August 2019pallidus receives afferent inputs from dopaminergic neurons from the
substantia nigra, thus making these neurons relevant to the study of
the basal ganglia.
Across all of the contrast agents and 5 different assessments of
toxicity, we measured dose-dependent toxicity that reflected the kinetic
stability of the agents. The consistency of these findings lends credibil-
ity to the result that GBCAs induce mitochondrial toxicity and death in
human neurons. We also used differentiated human neurons of a class
found within one of the most affected regions of the brain, which offers
a closer replica of the human brain than using rodent neurons. There-
fore, it is not unreasonable to project that neurons in the human brain
would experience some degree of the toxicity observed in cultured
human neurons.
These findings raise the important question of how clinically sig-
nificant the observed toxicity is for a patient obtaining contrast-
enhanced MRI. At 50 and 100 μM concentrations of GBCA, which
are within the concentration range measured in brain tissue of some au-
topsy patients21 after repeated contrast-enhanced MRI scans, the lower
stability agents consistently demonstrated toxic effects on mitochon-
drial function and cell viability. In the couple of instances where toxic-
ity from macrocyclic agents was statistically significant at these doses,
themagnitude of the effect was less. A single dose of GBCA for a single
contrast-enhancedMRI scan would not be expected to achieve this con-
centration of agent within the brain. However, with numerous repeated
administrations, and evidence that the lower stability agents may accu-
mulate and persist longer,17,18 our findings suggest that repeated admin-
istration, particularly of the lower kinetic stability GBCAs, could result
in neural toxicity.
Whether the cellular dysfunction could produce clinical effects
remains an unanswered question. Nevertheless, loss of any neurons
due to induced cell death is concerning, and any cellular toxicity may
accelerate cell death due to normal aging, which could become clini-
cally significant in older patients who have received multiple contrast-
enhanced MRIs over the course of their life. Likewise, extra caution
in utilizing these agents should be taken in the background of neural
disease, for instance Friedreich's ataxia, where toxicity to neurons such
as in the cerebellar dentate nucleus, which is important for initiation and
control of movement, could exacerbate the disease.43 As another exam-
ple, patients with multiple sclerosis receive repeated contrast-enhanced
MRI scans tomonitor the course of their disease. A recent study found a
correlation between higher T1 signal intensity in the dentate nucleus
and lower verbal fluency after correcting for disease severity.44 Al-
though the study does not prove causation, in light of our results that
GBCAs do cause neural toxicity, it underscores the importance of con-
trast agent selection, particularly in the background of neural disease.
More broadly, our findings support the growing body of evidence that,
when contrast enhancement is clinically necessary, utilizing the lowest
dose possible and contrast agents with higher kinetic stability and a
lower toxicity profile is prudent.
Future studies are needed to assess toxicity more than 1 week af-
ter administration to clarify how long toxic effects persist after a single
administration of GBCA. Furthermore, effects on other aspects of cel-
lular function remain to be tested. Likewise, the magnitude of effects
on cellular function of repeated administration of agents should ideally
be tested in human neural tissue. However, the complexity of such ex-
periments and difficulty in maintaining human brain tissue explants in
culture may make rodents better suited to such studies. It will also be
important to continue to monitor for clinical signs of neurological im-
pairment in patients receiving repeated administration of GBCAs over
their lifetime.
After much uncertainty as towhether GBCAs cause cellular tox-
icity, we now provide the first definitive evidence that these agents do
indeed induce mitochondrial toxicity and cell death in cultured human
neurons. The magnitude of the measured toxicity broadly increases as
the kinetic stability of the contrast agent decreases, and the lower462 www.investigativeradiology.com
Copyright © 2019 Wolters Kluwer Hstability agents induce toxicity at concentrations that fall within the
range detected in some autopsy patients. For all agents, the magnitude
of the toxicity increases with concentration. These results shed light
on a fundamental, long-standing question and highlight the importance
of a more complete understanding of the safety of these agents at the
cellular level.
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